Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
about
Cell wall assembly in Saccharomyces cerevisiaeSynergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformansComparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine modelIn vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolatesRapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TORInteractions of posaconazole and flucytosine against Cryptococcus neoformansAntifungal peptides: novel therapeutic compounds against emerging pathogensComparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformansDisk diffusion method for determining susceptibilities of Candida spp. to MK-0991.Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.Regulatory circuitry governing fungal development, drug resistance, and disease.Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds.Combination treatment of invasive fungal infections.In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistanceCryptococcal therapies and drug targets: the old, the new and the promising.Sphingolipids as targets for treatment of fungal infectionsIn vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points.Antifungal resistance and new strategies to control fungal infections.Voriconazole inhibits melanization in Cryptococcus neoformans.In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.The antifungal protein AFP from Aspergillus giganteus inhibits chitin synthesis in sensitive fungi.
P2860
Q24549234-B00F95C9-E8C8-4513-A320-D53D99DD6ACBQ28343929-5EA2BC74-289C-40E0-B313-943BF9AEE7F4Q28344362-132EE5A0-5725-4E66-A2EF-63AD69D6E4A2Q28345261-7792323C-3E71-4F7F-BC60-67F0D1DB19FDQ28361576-438D1F95-C982-45A8-89C1-E4222B39F177Q28362562-5B50BEB5-3DCB-4F1F-A2C6-B35768CAC17EQ28369443-98D332B1-493E-4A91-A9B1-DE2406D0DD8AQ28379123-DD4B6BB6-38A8-457E-AFD0-42E00832D45BQ33960454-DFAA4B79-BF58-4CEC-B3D3-8685F437D462Q33981480-CDBDC4A4-5D8C-4194-8F17-00816C71020EQ34190284-93C072D6-FEF8-4CA7-B97D-784C8C7F1114Q35127872-D35C8303-4037-4658-AC2A-6ECD44F642A1Q36011378-E1B4D8D7-5F44-4AAA-AAB3-5F84A1920DB0Q36047748-EBC0190F-91C0-4BC1-A036-15AF6A8F9884Q36911369-9EFFB7BD-F273-40A3-85F0-475987AAAD4DQ37122826-F5CE354F-31FC-48CC-ACCC-4E13C580EBBAQ38779568-C290C5AC-F194-4072-A60A-886F3FF811A4Q38833311-6B27840A-E3A0-4750-931B-B506E8E49B7FQ39651019-85084281-01AF-4713-9FF3-BFF43B115846Q39743420-56588EC9-F69D-40A0-B3B8-CBC3F16DCCE8Q39751373-467CAD6F-EA7A-432E-A564-D9226D737EDBQ40070453-CC5C4475-682D-4167-A82D-69D50F113CE4Q41772012-D4F5FF18-9624-4FD3-A59F-D452CCDB7487Q42222332-E02715ED-35E0-435E-943A-DE13DBEF117D
P2860
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@ast
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@en
type
label
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@ast
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@en
prefLabel
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@ast
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@en
P2860
P356
P1476
Pneumocandin L-743,872 enhance ...... yptococcus neoformans in vitro
@en
P2093
A Casadevall
S P Franzot
P2860
P304
P356
10.1128/AAC.41.2.331
P407
P577
1997-02-01T00:00:00Z